TNS2 shows promise as a diagnostic adjunct for discriminating GISTs from other gastric sarcomas [156], while TNS1 and TNS4 are increasingly incorporated into validated multi-gene signatures predicting survival and therapeutic response in bladder, colorectal, gastric, and lung cancers [50,121,161,163,164,165,166,167,168,169,170]. Here, TNS2 is linked to lung carcinoma.